NCT06922994View on ClinicalTrials.gov

Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)

PHASE2RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Arrhythmogenic Cardiomyopathy
Interventions
DRUG

Atorvastatin 80 mg/day

Atorvastatin 80mg/day will be administered for 18 months to patients affected by Arrhythmogenic Cardiomyopathy

DRUG

Placebo atorvastatin

One tablet of placebo will be administered for 18 months to patients affected by Arrhythmogenic Cardiomyopathy

Trial Locations (5)

20138

RECRUITING

Centro Cardiologico Monzino IRCSS, Milan

27100

RECRUITING

Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

60126

RECRUITING

Università Politecnica delle Marche, Ancona

80131

RECRUITING

AORN - Ospedali dei Colli, Napoli

80138

NOT_YET_RECRUITING

Università degli Studi di Napoli Federico II, Napoli

All Listed Sponsors
collaborator

Federico II University

OTHER

collaborator

Università Politecnica delle Marche

OTHER

collaborator

Ospedali dei Colli

OTHER

lead

Centro Cardiologico Monzino

OTHER